Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AMR: UK’s Subscription Scheme ‘One Way Forward,’ But New Economic Models Needed

Executive Summary

Stimulating the development of novel antibiotic drugs and diagnostics will require new funding models as part of the broader “push and pull” incentives strategy, says the director of health & life sciences at Innovate UK.

You may also be interested in...



WHO Outlines Priority Actions For Tackling AMR In 2024

An updated priority pathogen list, a review of the clinical pipeline for antibacterials, and high-level meetings with other global regulators are among the steps that will be taken by the World Health Organization in the year ahead to combat antimicrobial resistance.

UK SMEs Can Help Restock The AMR Toolbox, But Only If The ‘Broken Market’ Is Fixed

The UK must build greater capacity and offer funding to support small but “highly innovative” biotechs, which are instrumental in developing solutions to combat antimicrobial resistance, the chief executive of Scotland’s NovaBiotics argues.

Canada Tackles AMR With Drug Reserve List; Incentive Recommended To Motivate Antibiotic Development

A report advising Canada to adopt a subscription pull model to incentivize antibiotic drug development has also highlighted that only three of the 18 new antibiotics that entered the global market between 2010 and 2019 were marketed in Canada as of May 2023. Meanwhile, Health Canada is seeking feedback on its antimicrobial drug reverse list.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149718

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel